A $15 million-plus war chest from the Department of Defense and early-stage investors is now backing a bet on a single diagnostic tool: a tuberculosis screener for point-of-care clinics [Perplexity Sonar Pro, Jan 2026]. The Fremont-based startup Probius, founded in 2016, secured a grant from the Gates Foundation in January 2026 to advance the platform [Parsers VC, Jan 2026]. The goal is a result in under 30 minutes, with no sample preparation required.
The quantum wedge into diagnostics
Probius's core technology is a quantum electrochemical sensing (QES) platform. It is designed to identify and quantify molecules and single-cell organisms directly from raw samples, a process the company claims is a thousand times more informative than traditional methods [Perplexity Sonar Pro, Jan 2026]. This reagent-free, low-volume approach is the technical wedge. If it works at scale, it could move complex diagnostics out of centralized labs and into decentralized settings, starting with high-burden diseases like TB. The platform's broader ambition is multiscale phenotyping for predictive healthcare, but the immediate path to validation runs through a single, critical application.
The capital behind the chemistry
While specific round details are not publicly disclosed, the company's financial backing tells a story of patient, deep-tech capital. PitchBook data indicates a total raise of $12.9 million [PitchBook, 2026]. Other sources note over $15 million in funding from the DoD and early investors, suggesting a blend of non-dilutive government contracts and venture backing [Perplexity Sonar Pro, Jan 2026]. The investor syndicate includes Cota Capital, Zoic Capital, UCeed, and Plug and Play Tech Center, which also served as an accelerator [Crunchbase, 2026]. This is not a flashy, consumer-tech cap table. It is a group comfortable with long R&D cycles and the physics of sensor commercialization.
The founding team's background aligns with that thesis.
| Role | Name | Key Prior Experience |
|---|---|---|
| Co-Founder & CEO | Emmanuel P. Quevy | Director of MEMS Engineering at Silicon Laboratories; founded Silicon Clocks [The Org, 2026]. |
| Co-Founder & CTO | Chaitanya Gupta | Academic and industry experience in life sciences; associated with Stanford EE [ResearchGate, 2026]. |
Where the diagnostic road gets rough
For all its technical promise, Probius faces a gauntlet of commercial and regulatory challenges that define the deep-tech biotech playbook. The primary risk is not the science, but the path from a grant-funded prototype to a manufactured, approved, and adopted medical device. Competitors like SaponiQx are working on adjacent sensing technologies, and the entire point-of-care diagnostic market is crowded with promises that have stumbled on cost, complexity, or clinical validation. The company's reported headcount of 14 to 50 employees suggests a team heavily weighted toward R&D, with the commercial and operational scaling still ahead [PitchBook, 2026] [Perplexity Sonar Pro, Jan 2026]. The current hiring focus, as seen in open roles for Sensor Test and Product Test Engineers, confirms the priority is on hardening the core technology, not building a sales force [Lever.co, 2026].
The counter-bet is straightforward: can a platform born from a decade of R&D and defense contracts successfully navigate the radically different speed, cost sensitivity, and distribution channels of global health diagnostics? The Gates Foundation grant is a significant validator, but it is a starting gun, not a finish line.
The next validation milestone
All strategic questions for Probius now funnel toward the performance of its TB screener in the field. Success on the Gates Foundation project would provide the first real-world evidence that the QES platform works as advertised in a challenging, resource-limited environment. It would also create a beachhead case study to attract partnerships for other applications, from sepsis monitoring to broader infectious disease panels [ResearchGate, 2026]. Failure, or even significant delay, would raise hard questions about the platform's near-term viability outside the lab.
The company's financial runway, bolstered by the undisclosed 2023 funding event and non-dilutive capital, gives it time to find out [Crunchbase, 2026]. The bet from Cota Capital and Zoic Capital is that the team's sensor expertise can bridge the gap from physics to patient impact. For global health clinics waiting on a faster, simpler TB test, the real question is not about quantum electrochemistry. It's about when, or if, the technology arrives at the point of care.
Sources
- [Parsers VC, Jan 2026] Probius receives Gates Foundation grant for TB diagnostic | https://www.parsers.vc/announcements/probius-gates-foundation-grant-tb-diagnostic
- [Perplexity Sonar Pro, Jan 2026] Probius company overview and technology description
- [PitchBook, 2026] Probius company profile, funding, and employee count | https://pitchbook.com/profiles/company/229948-03
- [Crunchbase, 2026] Probius funding and investor information | https://www.crunchbase.com/organization/probius
- [The Org, 2026] Emmanuel Quevy professional background | https://theorg.com/org/probius/org-chart/emmanuel-quevy
- [ResearchGate, 2026] Chaitanya Gupta research profile | https://www.researchgate.net/profile/Chaitanya-Gupta
- [Lever.co, 2026] Probius job openings | https://jobs.lever.co/ProbiusDx